Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference

RARECAREnet Working Group

Research output: Contribution to journalArticle

Abstract

Germ-cell tumours (GCT) of the testis and penile squamous cell carcinoma (PeSCC) are a rare and a very rare uro-genital cancers, respectively. Both tumours are well defined entities in terms of management, where specific recommendations - in the form of continuously up-to-dated guide lines-are provided. Impact of these tumour is relevant. Testicular GCT affects young, healthy men at the beginning of their adult life. PeSCC affects older men, but a proportion of these patients are young and the personal consequences of the disease may be devastating. Deviation from recommended management may be a reason of a significant prognostic worsening, as proper treatment favourably impacts on these tumours, dramatically on GCT and significantly on PeSCC. RARECAREnet data may permit to analyse how survivals may vary according to geographical areas, histology and age, leading to assume that non-homogeneous health-care resources may impact the cure and definitive outcomes. In support of this hypothesis, some epidemiologic datasets and clinical findings would indicate that survival may improve when appropriate treatments are delivered, linked to a different accessibility to the best health institutions, as a consequence of geographical, cultural and economic barriers. Finally, strong clues based on epidemiological and clinical data support the hypothesis that treatment delivered at reference centres or under the aegis of a qualified multi-institutional network is associated with a better prognosis of patients with these malignancies. The ERN EURACAN represents the best current European effort to answer this clinical need.

Original languageEnglish
Pages (from-to)60-66
Number of pages7
JournalEuropean Journal of Surgical Oncology
Volume45
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Squamous Cell Carcinoma
Germ Cell and Embryonal Neoplasms
Neoplasms
Health Resources
Survival Analysis
Testis
Histology
Therapeutics
Economics
Testicular Germ Cell Tumor
Delivery of Health Care
Survival
Health

Keywords

  • Carcinoma
  • Community network
  • Europe
  • Germ cell and embryonal
  • Neoplasms
  • Penis neoplasms
  • Rare diseases
  • Squamous cell
  • Survival
  • Tertiary care centres
  • Testicular neoplasms

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Testicular germ-cell tumours and penile squamous cell carcinoma : Appropriate management makes the difference. / RARECAREnet Working Group.

In: European Journal of Surgical Oncology, Vol. 45, No. 1, 01.01.2019, p. 60-66.

Research output: Contribution to journalArticle

@article{5ff238eaf3a145b196f3f36a82cc8be4,
title = "Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference",
abstract = "Germ-cell tumours (GCT) of the testis and penile squamous cell carcinoma (PeSCC) are a rare and a very rare uro-genital cancers, respectively. Both tumours are well defined entities in terms of management, where specific recommendations - in the form of continuously up-to-dated guide lines-are provided. Impact of these tumour is relevant. Testicular GCT affects young, healthy men at the beginning of their adult life. PeSCC affects older men, but a proportion of these patients are young and the personal consequences of the disease may be devastating. Deviation from recommended management may be a reason of a significant prognostic worsening, as proper treatment favourably impacts on these tumours, dramatically on GCT and significantly on PeSCC. RARECAREnet data may permit to analyse how survivals may vary according to geographical areas, histology and age, leading to assume that non-homogeneous health-care resources may impact the cure and definitive outcomes. In support of this hypothesis, some epidemiologic datasets and clinical findings would indicate that survival may improve when appropriate treatments are delivered, linked to a different accessibility to the best health institutions, as a consequence of geographical, cultural and economic barriers. Finally, strong clues based on epidemiological and clinical data support the hypothesis that treatment delivered at reference centres or under the aegis of a qualified multi-institutional network is associated with a better prognosis of patients with these malignancies. The ERN EURACAN represents the best current European effort to answer this clinical need.",
keywords = "Carcinoma, Community network, Europe, Germ cell and embryonal, Neoplasms, Penis neoplasms, Rare diseases, Squamous cell, Survival, Tertiary care centres, Testicular neoplasms",
author = "{RARECAREnet Working Group} and Nicola Nicolai and Davide Biasoni and Catanzaro, {Mario A.} and Maurizio Colecchia and Annalisa Trama and Monika Hackl and Eycken, {Elizabeth Van} and Kris Henau and Nadya Dimitrova and Mario Sekerija and Ladislav Dušek and Margit M{\"a}gi and Nea Malila and Maarit Leinonen and Michel Velten and Xavier Troussard and Veronique Bouvier and Guizard, {Anne Val{\'e}rie} and Bouvier, {Anne Marie} and Patrick Arveux and Marc Maynadi{\'e} and Woronoff, {Anne Sophie} and Michel Robaszkiewic and Isabelle Baldi and Alain Monnereau and Brigitte Tretarre and Marc Colonna and Florence Molini{\'e} and Simona Bara and Claire Schvartz and B{\'e}n{\'e}dicte Lap{\^o}tre-Ledoux and Pascale Grosclaude and Roland Stabenow and Sabine Luttmann and Alice Nennecke and Jutta Engel and Gabriele Schubert-Fritschle and Jan Heidrich and Bernd Holleczek and J{\'o}nasson, {J{\'o}n Gunnlaugur} and Kerri Clough-Gorr and Harry Comber and Diego Serraino and {De Angelis}, Roberta and Sandra Mallone and Andrea Tavilla and Silvia Rossi and Mariano Santaquilani and Valerio Gennaro and Maria Gentilini",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ejso.2018.02.006",
language = "English",
volume = "45",
pages = "60--66",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Testicular germ-cell tumours and penile squamous cell carcinoma

T2 - Appropriate management makes the difference

AU - RARECAREnet Working Group

AU - Nicolai, Nicola

AU - Biasoni, Davide

AU - Catanzaro, Mario A.

AU - Colecchia, Maurizio

AU - Trama, Annalisa

AU - Hackl, Monika

AU - Eycken, Elizabeth Van

AU - Henau, Kris

AU - Dimitrova, Nadya

AU - Sekerija, Mario

AU - Dušek, Ladislav

AU - Mägi, Margit

AU - Malila, Nea

AU - Leinonen, Maarit

AU - Velten, Michel

AU - Troussard, Xavier

AU - Bouvier, Veronique

AU - Guizard, Anne Valérie

AU - Bouvier, Anne Marie

AU - Arveux, Patrick

AU - Maynadié, Marc

AU - Woronoff, Anne Sophie

AU - Robaszkiewic, Michel

AU - Baldi, Isabelle

AU - Monnereau, Alain

AU - Tretarre, Brigitte

AU - Colonna, Marc

AU - Molinié, Florence

AU - Bara, Simona

AU - Schvartz, Claire

AU - Lapôtre-Ledoux, Bénédicte

AU - Grosclaude, Pascale

AU - Stabenow, Roland

AU - Luttmann, Sabine

AU - Nennecke, Alice

AU - Engel, Jutta

AU - Schubert-Fritschle, Gabriele

AU - Heidrich, Jan

AU - Holleczek, Bernd

AU - Jónasson, Jón Gunnlaugur

AU - Clough-Gorr, Kerri

AU - Comber, Harry

AU - Serraino, Diego

AU - De Angelis, Roberta

AU - Mallone, Sandra

AU - Tavilla, Andrea

AU - Rossi, Silvia

AU - Santaquilani, Mariano

AU - Gennaro, Valerio

AU - Gentilini, Maria

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Germ-cell tumours (GCT) of the testis and penile squamous cell carcinoma (PeSCC) are a rare and a very rare uro-genital cancers, respectively. Both tumours are well defined entities in terms of management, where specific recommendations - in the form of continuously up-to-dated guide lines-are provided. Impact of these tumour is relevant. Testicular GCT affects young, healthy men at the beginning of their adult life. PeSCC affects older men, but a proportion of these patients are young and the personal consequences of the disease may be devastating. Deviation from recommended management may be a reason of a significant prognostic worsening, as proper treatment favourably impacts on these tumours, dramatically on GCT and significantly on PeSCC. RARECAREnet data may permit to analyse how survivals may vary according to geographical areas, histology and age, leading to assume that non-homogeneous health-care resources may impact the cure and definitive outcomes. In support of this hypothesis, some epidemiologic datasets and clinical findings would indicate that survival may improve when appropriate treatments are delivered, linked to a different accessibility to the best health institutions, as a consequence of geographical, cultural and economic barriers. Finally, strong clues based on epidemiological and clinical data support the hypothesis that treatment delivered at reference centres or under the aegis of a qualified multi-institutional network is associated with a better prognosis of patients with these malignancies. The ERN EURACAN represents the best current European effort to answer this clinical need.

AB - Germ-cell tumours (GCT) of the testis and penile squamous cell carcinoma (PeSCC) are a rare and a very rare uro-genital cancers, respectively. Both tumours are well defined entities in terms of management, where specific recommendations - in the form of continuously up-to-dated guide lines-are provided. Impact of these tumour is relevant. Testicular GCT affects young, healthy men at the beginning of their adult life. PeSCC affects older men, but a proportion of these patients are young and the personal consequences of the disease may be devastating. Deviation from recommended management may be a reason of a significant prognostic worsening, as proper treatment favourably impacts on these tumours, dramatically on GCT and significantly on PeSCC. RARECAREnet data may permit to analyse how survivals may vary according to geographical areas, histology and age, leading to assume that non-homogeneous health-care resources may impact the cure and definitive outcomes. In support of this hypothesis, some epidemiologic datasets and clinical findings would indicate that survival may improve when appropriate treatments are delivered, linked to a different accessibility to the best health institutions, as a consequence of geographical, cultural and economic barriers. Finally, strong clues based on epidemiological and clinical data support the hypothesis that treatment delivered at reference centres or under the aegis of a qualified multi-institutional network is associated with a better prognosis of patients with these malignancies. The ERN EURACAN represents the best current European effort to answer this clinical need.

KW - Carcinoma

KW - Community network

KW - Europe

KW - Germ cell and embryonal

KW - Neoplasms

KW - Penis neoplasms

KW - Rare diseases

KW - Squamous cell

KW - Survival

KW - Tertiary care centres

KW - Testicular neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85043337936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043337936&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2018.02.006

DO - 10.1016/j.ejso.2018.02.006

M3 - Article

C2 - 29526370

AN - SCOPUS:85043337936

VL - 45

SP - 60

EP - 66

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 1

ER -